DescriptionProductAvailABIlity:InStock(deliverywithin2-3businessdays,noextrachargefordrop-shipping).Ordering:ToplaceanorderviacreditcardorPOuseAddtoCartbutton(creatinganaccountisnotrequired).TransfectionReagentfor 4T1Cells(BreastCancerCells,CRL-2539)TwocomponentformulationenhanceslipidmediatedtransfectionefficiencyOptimizedeasy-to-usetransfectionprotocolprovidedfortransfectionofsiRNA,DNA,mRNA,andmicroRNAKitincludesTransfectionEnhancerreagentandrecommendedtransfectionprotocolHightransfectionefficacyinthe presenceofserumExpandyourRNAiapplicationwithareagentoptimizedfordeliveryofbothsiRNAandplasmidReproducIBLetransfectionresultsWorkswellforstandardreversetransfectionandhigh-throughputapplicationsDownloadinvitro4T1transfectionprotocol:[PDF]Download 4T1CRISPR/Cas9transfectionprotocol:[PDF]DownloadPowerPointpresentationfor4T1 cellstransfectionkit:[PPT]DevelopedandmanufacturedbyAltogenBiosystemsTransfectionEfficiency:Reagentexhibitsatleast67%transfectionefficiencyofsiRNAdelivery.Transfectionefficiencywasdeterminedbyreal-timeRT-PCR.TransfectionProtocolandMSDS:DownloadAltogenBiosystems4T1TransfectionProtocol:[PDF]DownloadMSDS:[PDF]4T1CellLine:Triple-negativebreastcancerisanuncommonsubtypeofbreastcancerthatlacksreceptorsforestrogen,progesterone,orHER2.Itisaninvasivetypeofcancerwithlimitedtreatmentoptions.The4T1triple-negativecelllinewasestablishedfromthetumorofthemammaryglandinamouse(Musmusculus).Thiscelllinewasselectedasresistantto6-thioguaninewithoutmutagentreatment.Thistypeoftumoreasily,andquicklyspreadsthroughoutthebodyofthemiceiteffects.ThistumOrigeniccelllineexhibitsepithelialcellularmorphology.Thesecellsareusefulmodelincancerresearch.The4T1celllineisespeciallyvaluableforstageIVhumanbreastcancerstudiessincetumorfromthiscelllinemimicshumanbreastcancerandeasilymetastasizesthroughmice,makingasuitablebreastcancermodel.The4T1murinebreastcancercelllineistransplantableandhastheabilitytoexhibitsimilaraggressivephenotypetothehumanbreastcancer.AltogenBiosystemsofferspre-optimizedtransfectionkitsforthe4T1cellline.Data:Figure1.CyclophilinBsilencingefficiencywasdeterminedbyqRT-PCRinthe4T1cellstransfectedbyCyclophilinBsiRNAornon-silencingsiRNAcontrolfollowingtherecommendedtransfectionprotocol.CyclophilinmRNAexpressionlevelsweremeasured48hourspost-transfection.18SrRNAlevelswereusedtonormalizetheCyclophilinBdata.Valuesarenormalizedtountreatedsample.Dataarepresentedasmeans±SD(n=6).Figure2.ProteinexpressionofCyclophilinBin4T1cells.DNAplasmidexpressingCyclophilinBorsiRNAtargetingCyclophilinBweretransfectedinto4T1cellsfollowingAltogenBiosystemstransfectionprotocol.At72hourspost-transfectionthecellswereanalyzedbyWesternBlotforproteinexpressionlevels(normalizedbytotalprotein,10µgoftotalproteinloadedpereachwell).Untreatedcellsusedasanegativecontrol.Selected invivo transfectionproductcitations(ALTOGEN® INVIVO TransfectionKits usedinthefollowingpublications):Nature.2008454(7203):523-7.Innateimmunityinducedbycomposition-dependentRIG-I…Saitoetal[PDF]Am JPathology.2010177(4):1870-80.RoleofocularcomplementfactorHinamurinemodel…Lyzogubovetal[PDF]RNA.201016(11):2108-19.RNaseLreleasesasmallRNAfromHCVRNAthatrefolds…Malathietal[PDF]Hypertension.201463(2):353-61.Tissuetransglutaminasecontributesto…Liuetal[PDF]JounalofBIOLOGicalChemistry.2012287(4):2907.Chaperoningofmutantp53protein…Gognaetal [PDF]J TranslMed.201015;8:133.Preventionofhyperglycemia-inducedmyocardialapoptosis…Zhangetal[PDF]MolCellBiol.201333(7).SCO2inducesp53-mediatedapoptosisbyThr845phosphorylation…Madanetal[PDF]RequestaQuotefor4T1TransfectionReagentAltogenBiosystems:AltogenBiosystemsisalifesciencescompany thatoffers celltype-specificandpre-optimizedtransfectionproducts, elecroporationkits,andinvivodeliveryreagents.Advancedformulationofreagentsandoptimizedtransfectionprotocolsprovideefficientintracellulardeliveryofprotein,DNA,mRNA,shRNA andsiRNAmolecules.Readmore abouttransfectiontechnologyatAltogen’sTransfectionResource.AltogenResearchServices:AltogenLabsprovidesGLP-compliantcontractresearchstudiesforpre-clinicalresearch,INDapplications,anddrugdevelopment.BiologyCROservices include:Xenograftmodels(30+),developmentofstablecelllines,ELISAassaydevelopment,cell-basedandtissuetargetedRNAistudies,safetypharm/toxassays,andotherstudies(visitAltogenLabs.com).VolumeOptions:0.5ml(Catalog#1163)1.5ml(Catalog#1164)1.5mlCRISPR(Catalog#2208)8.0ml(Catalog#7017)
Altogen Biosystems全国代理部分产品列表：
|
货号
|
产品
|
规格
|
价格（美元）
|
|
5030
|
|
|
|
|
1703
|
A204 Transfection Reagent (Rhabdomyosarcoma)
|
0.5ml
|
170
|
|
1704
|
A204 Transfection Reagent (Rhabdomyosarcoma)
|
1.5ml
|
348
窗体顶端
窗体底端
|
|
2101
|
A204 Transfection Reagent (Rhabdomyosarcoma)
|
1.5ml CRISPR
|
548
窗体顶端
窗体底端
|
|
7018
|
A204 Transfection Reagent (Rhabdomyosarcoma)
|
8.0ml
|
1044
窗体顶端
窗体底端
|
|
1167
|
A375 Cells Transfection Reagent (CRL-1619)
|
0.5ml
|
195
|
|
1168
|
A375 Cells Transfection Reagent (CRL-1620)
|
1.5ml
|
427
|
|
2102
|
A375 Cells Transfection Reagent (CRL-1621)
|
1.5ml CRISPR
|
627
|
|
1169
|
A375 Cells Transfection Reagent (CRL-1622)
|
8.0ml
|
1281
|
|
5030
|
Nanoparticle In Vivo Transfection Reagent
|
0.5 ml - 10 injections
|
445
|
|
5010
|
LIPID In Vivo Transfection Reagent
|
0.5 ml - 10 injections
|
405
|
|
5040
|
PEG-Liposome In Vivo Transfection Reagent
|
0.5 ml - 10 injections
|
465
|
|
5020
|
POLYMER In Vivo Transfection Reagent
|
0.5 ml - 10 injections
|
425
|
|
5050
|
Pancreas In Vivo Transfection Kit
|
0.5 ml - 10 injections
|
495
|
|
5060
|
Liver In Vivo Transfection Kit
|
0.5 ml - 10 injections
|
495
|
|
5070
|
Kidney In Vivo Transfection Kit
|
0.5 ml - 10 injections
|
495
|
|
1721
|
BMS2 Transfection Reagent (Bone Marrow Cells)
|
0.5 ml
|
231
|
|
6345
|
C6 Transfection Reagent (Glioma Cells, CCL-107)
|
0.5 ml
|
199
|
|
6803
|
DLD-1 Transfection Reagent (Colon Cancer, CCL-221)
|
0.5 ml
|
201
|
|
1775
|
HUH-7 Transfection Reagent (Liver Cancer Cells)
|
0.5 ml
|
179
|
